Abivax Announces Board Resignation

Abivax SA, a biotech firm developing therapies for chronic inflammatory diseases, announced a board change. Dr. Philippe Pouletty, representing Truffle Capital, resigns as director effective December 31, 2024. This follows his recent appointment as Chairman and acting CEO at another biotech company.

Dr. Pouletty, a key figure since Abivax's inception in 2013, expressed pride in developing obefazimod and confidence in Abivax's leadership. He anticipates continued support from Truffle Capital, especially with the upcoming Phase 3 ABTECT data in 2025.

Sylvie Grégoire, Chair of Abivax's Board, acknowledged Dr. Pouletty's contributions. She noted his leadership was crucial in advancing obefazimod, which targets ulcerative colitis. The company seeks a new board member to further progress its late-stage pipeline.